文献速递乳腺外科

局部晚期乳腺癌新辅助化疗后保留乳头乳房切除术与传统乳房切除术的倾向评分匹配长期肿瘤学结局分析

A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer.
PubMed 文献 · Ann Surg · 2020-11-18

该倾向评分匹配研究纳入850例接受新辅助化疗的临床IIB-IIIC期乳腺癌患者,匹配后418例分为保留乳头乳房切除加即刻重建组与传统乳房切除组。中位随访约70-74个月,两组6年局部无复发生存率、无病生存率、无远处转移生存率和总生存率均无显著差异。术前肿瘤累及乳晕下区域但化疗后影像学缓解者,可尝试保留乳头乳晕复合体。

要点

  • 局部晚期乳腺癌新辅助化疗后,保留乳头乳房切除加即刻重建与传统乳房切除的长期肿瘤学结局相当。
  • 术前肿瘤累及乳晕下区域者,若化疗后影像学显示乳晕复合体受累缓解,可尝试保留乳头。
  • 该研究为倾向评分匹配的回顾性分析,保留乳头乳房切除在局部晚期乳腺癌中的肿瘤学安全性需进一步前瞻性验证。

核心结论

  • 局部晚期乳腺癌患者接受新辅助化疗后,保留乳头乳房切除加即刻重建与传统乳房切除 alone 的长期肿瘤学结局相当。
  • 术前肿瘤延伸至乳晕下区域的患者,若新辅助化疗后影像学显示乳头乳晕复合体受累消退,可尝试保留乳头乳房切除。

研究设计与样本

  • 回顾性倾向评分匹配研究,研究组为850例临床IIB至IIIC期接受新辅助化疗后行保留乳头乳房切除加即刻重建或传统乳房切除 alone 的乳腺癌患者。
  • 经倾向评分匹配后,418例患者纳入分析。
  • 采用Kaplan-Meier法计算生存率,log-rank检验比较保留乳头乳房切除组与传统乳房切除组。

主要发现

  • 匹配后,保留乳头乳房切除组平均随访70±25个月,传统乳房切除组74±27个月(P=0.181)。
  • 两组6年局部无复发生存率分别为91.6%与95.8%(P=0.239),无显著差异。
  • 两组6年无病生存率分别为70.5%与73.4%(P=0.583),无显著差异。
  • 两组6年无远处转移生存率分别为79.8%与77.4%(P=0.320),无显著差异。
  • 两组6年总生存率分别为87.6%与84.8%(P=0.465),无显著差异。

关键数值与推荐

  • 保留乳头乳房切除组中30例术前肿瘤延伸至乳晕下区域,新辅助化疗后乳头乳晕复合体成功保留,未观察到乳头复发。

临床怎么用

  • 对于局部晚期乳腺癌接受新辅助化疗的患者,保留乳头乳房切除加即刻重建可作为传统乳房切除的替代选择之一,需结合多学科评估。
  • 术前肿瘤累及乳晕下区域者,若化疗后影像学评估乳头乳晕复合体受累消退,可考虑尝试保留乳头乳房切除。

局限性

  • 本研究为倾向评分匹配的回顾性分析,存在选择偏倚可能。
  • 保留乳头乳房切除在局部晚期乳腺癌中的肿瘤学安全性仍需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the long-term oncologic outcomes of nipple-sparing mastectomy (NSM) with those of conventional mastectomy (CM) in patients with locally advanced breast cancer (LABC) receiving neoadjuvant chemotherapy (NACT). SUMMARY OF BACKGROUND DATA: NSM has been increasingly implemented in patients with breast cancer. However, oncologic efficacy of NSM in patients with LABC has not been sufficiently demonstrated. METHODS: The study group comprised 850 patients with clinical stage IIB to IIIC breast cancer who underwent NACT followed by either NSM and immediate breast reconstruction or CM alone. After propensity score-matching, 418 patients were included in the analysis. Local recurrence-free survival, disease-free survival (DFS), distant metastasis-free survival, and overall survival (OS) rates were calculated using the Kaplan-Meier method and compared using log-rank tests between the NSM and CM groups. RESULTS: After matching, the mean follow-up period was 70 ± 25 months for the NSM group and 74 ± 27 months for the CM group ( P = 0.181). There were no significant differences between the groups in terms of 6-year local recurrence-free survival (91.6% vs. 95.8%; P = 0.239), DFS (70.5% vs. 73.4%; P = 0.583), distant metastasis-free survival (79.8% vs. 77.4%; P = 0.320), or OS (87.6% vs. 84.8%; P = 0.465) rates. Additionally, we identified 30 patients in the NSM group who initially presented with tumor extension in the subareolar area; the nipple-areola complex was successfully preserved after NACT, and no recurrence at the nipple was observed in these patients. CONCLUSIONS: In this matched control study, we demonstrated comparable long-term oncologic outcomes between NSM with immediate reconstruction and CM alone after NACT for LABC. In patients who had tumors extending to the subareolar area before NACT, NSM can be tried if tumor involvement of the nipple-areola complex appears resolved on imaging studies after chemotherapy.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Wu ZY, Han HH, Kim HJ, et al. A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer. Ann Surg. 2020. PMID: 33201107. doi:10.1097/SLA.0000000000004416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。